Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Selcia Appoints New Director of Discovery

Published: Wednesday, October 09, 2013
Last Updated: Wednesday, October 09, 2013
Bookmark and Share
Appointment of John Davis to the role of Director of Discovery.

Selcia Limited has appointed John Davis to the newly created role of Director of Discovery.

John joins Selcia from Convergence Pharmaceuticals, where he served as Head of Biology between 2010 and 2013 and was a co-founder of the company.

Dr. Hans Fliri, chairman and CEO of Selcia Ltd., said “We are delighted that John has joined Selcia, his extensive drug discovery expertise will be a tremendous asset to our business. We have an ambitious plan to grow and further develop Selcia’s integrated drug discovery service. John’s knowledge of the international pharmaceutical and biotechnology industries will undoubtedly help us achieve that goal.”

John’s particular research interests have been focussed on cardiovascular, oncology and CNS disorders. Much of his 20 years’ drug discovery experience was gained at SmithKline Beecham and GlaxoSmithKline and encompasses a range of target classes including ion channels, GPCRs, kinases and proteases.

With his deep experience of target identification through to clinical proof of concept, John has been responsible for the discovery of 11 small molecule and biologic development candidates, and the preclinical pharmacology supporting two assets achieving positive Phase II and one product.

At GSK John was variously director of neurodegeneration research, a director of discovery technologies and director of biology for pain and epilepsy research, and was also instrumental in the formation and management of several large collaborations with universities.

John originally trained as a biochemist and has a PhD from Cambridge University. He was a research fellow at the Ludwig Institute for Cancer Research and Salk Institute for six years before joining SmithKline Beecham in 1993. He has over 100 peer reviewed publications and patents to his name.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

University of Edinburgh and Selcia in £2.5 m Bid
Edinburgh University and Selcia research new drugs to combat sleeping sickness disease.
Tuesday, February 04, 2014
Selcia Awarded GMP Certificate for Preparation and Carbon-14 Labelling of APIs for Clinical Trials
Extended capability expected to shorten the timeframe for commencement of client’s key Phase 1 clinical trials.
Thursday, December 09, 2010
Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!